据智通财经APP了解，"合成致死"是一种新兴的抗癌机制，其原理在于：当细胞中两个特定通路同时出 现缺陷时，会导致细胞死亡，而单一通路的缺陷则不会产生该后果。在肿瘤治疗中，通过识别肿瘤细胞 因致癌突变而产生的合成致死对，针对性靶向其配对通路，能够实现选择性杀伤肿瘤细胞的效果。该机 制不仅在理论上具有高度靶向性，能在杀灭癌细胞的同时保护正常组织，更在扩大药物作用靶点、克服 耐药性问题以及协同联合治疗等方面展现出显著潜力。 从财务数据来看，尽管英派药业通过对外授权及药品销售获得部分收入，公司在2023年、2024年全年及 2025年上半年仍分别录得约1.99亿元、2.55亿元和1.29亿元的亏损，主要源于高强度的研发支出。截至 2025年6月30日，公司现金及现金等价物仅余2.1亿元，现金流状况趋于紧张。 | | 截至12月31日止年度 | | 截至6月30日止六個月 | | | --- | --- | --- | --- | --- | | | 2023年 | 2024年 | 2024年 | 2025年 | | | (人民幣千元)(人民幣千元) | | (人民幣千元) | (人民幣千元) | | | | | (未 ...

每经记者｜金喆 每经编辑｜魏官红 恒生医疗保健业指数 港股创新药ETF (HSCICH) (513120) 周内涨跌 - 2.76% 周内涨跌 -1.60% - A股当周涨跌幅 - 信立泰 博瑞医药 周内涨跌 | | | 30% | 周内涨跌 38.77% - 港股当周涨跌幅 - 晶泰控股 映恩生物 周内涨跌 ↑15.26% | 周内涨跌 | 15.42% 聚焦前沿 热门赛道 全球首个皮下注射抗体药物偶联物 启动II期临床 适应证为晚期非小细 胞肺癌 一周热股 映恩生物-B领跌创新药板块,ADC (抗体偶联药物)有"泡沫" 资本动向 英派药业递表港交所 1款产品上市、 今年上半年净亏损1.29亿元 | 《掘金创新药》 栏目由每日经济新闻推出，每周一期 | | --- | | 解读新药研发进展与趋势 剖析产品竞争力与市场前景 | | 洞察医药资本脉络 见证医药产业高质量发展 | | 数据来源：东方财富App、富途牛牛 | 资本眼 一周行情 9月22日至9月26日，医药生物指数下跌1.69%，跑输上证指数1.04个百分点。创新药（BK1106）周内下跌2.10%。恒生医疗保健业指数（HSCICH）周下跌 2.76 ...

Core Viewpoint - Crystal Technology (晶泰科技) announced a significant milestone in clinical research for the next-generation PRMT5 inhibitor PEP08, which has received clinical trial approvals from regulatory bodies in Australia and Taiwan, marking the initiation of Phase I clinical trials [1][3]. Group 1: Clinical Development - PEP08 has been approved for clinical trials by the Human Research Ethics Committee (HREC) in Australia, the Therapeutic Goods Administration (TGA), and the Taiwan Food and Drug Administration (TFDA) [1]. - The approval signifies a major step forward in the collaboration between Crystal Technology and PharmaEngine, leading to milestone payments for Crystal Technology [1][3]. Group 2: Drug Characteristics - PRMT5 is a key enzyme overexpressed in various cancers, and inhibiting its activity can lead to a "synthetic lethality" effect in tumors with homozygous deletion of MTAP, which accounts for approximately 10-15% of human cancers [1]. - PEP08, as a second-generation PRMT5 inhibitor, exhibits high activity and selectivity, forming a stable ternary complex with PRMT5, specifically targeting MTAP-deficient tumor cells while minimizing effects on normal cells [2][3]. Group 3: Preclinical Research - Preclinical data indicate that PEP08 shows significant advantages in toxicity and safety compared to first-generation non-selective PRMT5 inhibitors, with good blood-brain barrier penetration and ideal overall drug-like properties [3]. - PEP08 demonstrates strong in vivo efficacy at lower doses in multiple animal efficacy models, suggesting potential best-in-class effects and broad potential for combination with other therapies [3].

Core Viewpoint - JingTai Technology (02228) announced a significant clinical development milestone for the next-generation PRMT5 inhibitor PEP08, which has received clinical trial approvals from regulatory bodies in Australia and Taiwan, marking the initiation of Phase I clinical trials [1][3]. Group 1: Clinical Development - PEP08 has achieved important clinical research milestones, receiving approvals from the Human Research Ethics Committee (HREC) and the Therapeutic Goods Administration (TGA) in Australia, as well as the Taiwan Food and Drug Administration (TFDA) [1]. - The project has led to milestone payments for JingTai Technology, confirming the progress made in collaboration with PharmaEngine, Inc. [1][3]. Group 2: Drug Characteristics - PRMT5 is a key enzyme overexpressed in various cancers, and inhibiting its activity can lead to a "synthetic lethality" effect in tumors with homozygous deletion of MTAP, which accounts for approximately 10-15% of human cancers [1]. - PEP08, as a second-generation PRMT5 inhibitor, exhibits high activity and selectivity, forming a stable ternary complex with PRMT5 through an MTA cooperative binding mode, specifically targeting MTAP-deficient tumor cells while minimizing effects on normal cells [2]. Group 3: Preclinical Research and Efficacy - Preclinical data indicate that PEP08 shows significant advantages in toxicity and safety compared to first-generation non-selective PRMT5 inhibitors, with good blood-brain barrier penetration and ideal overall drug-like properties [3]. - PEP08 demonstrates strong in vivo efficacy at lower doses in multiple animal efficacy models, showcasing potential best-in-class effects and broad potential for combination with other therapies [3].

据介绍，SIM0508是抗肿瘤"合成致死"机制的最新成果，由先声再明自主研发，也是中国首个获批进入 临床研究的Polθ抑制剂。SIM0508已取得中美两国IND批件，目前处于临床I期。早期临床研究显示， SIM0508安全性和耐受性良好，未观察到明显的血液学毒性，提示其与PARP抑制剂或化疗药物联用产 生的叠加血液毒性风险较低，有潜力成为一款治疗多种HRD实体瘤的创新抗癌疗法。其相关研究数据 将在未来的学术年会中公布。 消息面上，据先声药业官微消息，集团旗下抗肿瘤创新药公司先声再明宣布，其自主研发的抗肿瘤候选 药物——DNA聚合酶θ(Polθ)小分子抑制剂SIM0508已获得国家药品监督管理局(NMPA)批准，联合奥拉 帕利开展治疗晚期实体瘤的临床试验。 智通财经APP获悉，先声药业(02096)涨近3%，截至发稿，涨2.58%，报12.7港元，成交额5562.95万港 元。 ...

Core Viewpoint - Xiansheng Pharmaceutical (02096) has seen a nearly 3% increase in stock price following the announcement of its innovative anti-tumor drug candidate SIM0508 receiving approval from the National Medical Products Administration (NMPA) for clinical trials in combination with Olaparib for the treatment of advanced solid tumors [1] Company Summary - Xiansheng Pharmaceutical's subsidiary, Xiansheng Zaiming, announced that its self-developed anti-tumor candidate drug, DNA polymerase theta (Polθ) small molecule inhibitor SIM0508, has been approved for clinical trials [1] - SIM0508 is the first Polθ inhibitor approved for clinical research in China and has also received IND approvals in both China and the United States, currently in Phase I clinical trials [1] - Early clinical studies indicate that SIM0508 has good safety and tolerability, with no significant hematological toxicity observed, suggesting a low risk of additive hematological toxicity when used in combination with PARP inhibitors or chemotherapy drugs [1] Industry Summary - The approval of SIM0508 represents a significant advancement in the "synthetic lethality" mechanism for anti-tumor therapies, highlighting the potential for innovative cancer treatments targeting various homologous recombination deficiency (HRD) solid tumors [1] - Relevant research data regarding SIM0508 will be presented at upcoming academic conferences, indicating ongoing developments in the field of oncology [1]

中国生物制药(01177)公布，该集团自主研发的创新药TQB3122"PARP1抑制剂"的新药临床试验申请 (IND)已获得中国国家药品监督管理局(NMPA)受理，拟用于治疗晚期恶性肿瘤。 目前，全球尚无同靶点药物获批上市。该集团将探索TQB3122在晚期实体瘤中的安全性与疗效，有望为 全球患者提供新的治疗选择。 TQB3122是一款具有高选择性和血脑屏障穿透能力的PARP1抑制剂，通过双重机制发挥抗肿瘤作用：一 方面，竞争性抑制PARP1酶的催化活性，阻断DNA单链断裂修复;另一方面，通过"捕获"机制稳定DNA- PARP复合物，阻碍复制叉进展。基于"合成致死"塬理，TQB3122可选择性杀伤BRCA突变或同源重组 缺陷的肿瘤细胞。研究显示，TQB3122在多个肿瘤模型中疗效显著，且脑组织分布能力突出，是颅内肿 瘤治疗的潜在新选择。 ...

格隆汇8月11日丨中国生物制药(01177.HK)公告，集团自主研发的创新药TQB3122「PARP1抑制剂」的 新药临床试验申请(IND)已获得中国国家药品监督管理局(NMPA)受理，拟用于治疗晚期恶性肿瘤。 TQB3122是一款具有高选择性和血脑屏障穿透能力的PARP1抑制剂，通过双重机制发挥抗肿瘤作用：一 方面，竞争性抑制PARP1酶的催化活性，阻断DNA单链断裂修复；另一方面，通过「捕获」机制稳定 DNA-PARP复合物，阻碍复制叉进展。基于「合成致死」原理，TQB3122可选择性杀伤BRCA突变或同 源重组缺陷的肿瘤细胞。研究显示，TQB3122在多个肿瘤模型中疗效显著，且脑组织分布能力突出，是 颅内肿瘤治疗的潜在新选择。 目前，全球尚无同靶点药物获批上市。集团将探索TQB3122在晚期实体瘤中的安全性与疗效，有望为全 球患者提供新的治疗选择。 ...

TQB3122是一款具有高选择性和血脑屏障穿透能力的PARP1抑制剂，通过双重机制发挥抗肿瘤作用：一 方面，竞争性抑制PARP1酶的催化活性，阻断DNA单链断裂修复;另一方面，通过"捕获"机制稳定DNA- PARP复合物，阻碍复制叉进展。基于"合成致死"塬理，TQB3122可选择性杀伤BRCA 突变或同源重组 缺陷的肿瘤细胞。研究显示，TQB3122在多个肿瘤模型中疗效显著，且脑组织分布能力突出，是颅内肿 瘤治疗的潜在新选择。 目前，全球尚无同靶点药物获批上市。该集团将探索TQB3122在晚期实体瘤中的安全性与疗效，有望为 全球患者提供新的治疗选择。 智通财经APP讯，中国生物制药(01177)公布，该集团自主研发的创新药TQB3122"PARP1抑制剂"的新药 临床试验申请(IND)已获得中国国家药品监督管理局 (NMPA)受理，拟用于治疗晚期恶性肿瘤。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 目前，全球尚無同靶點藥物獲批上市。本集團將探索TQB3122在晚期實體瘤中的安全性與療效，有 望為全球患者提供新的治療選擇。 承董事會命 中國生物製藥有限公司 主席 謝其潤 香港，二零二五年八月十一日 1 （於開曼群島註冊成立之有限公司） 網站：www.sinobiopharm.com （股份編號：1177） 自願公告 TQB3122「PARP1抑制劑」臨床試驗申請獲NMPA受理 中國生物製藥有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董事會」）宣佈，本集團自 主研發的創新藥TQB3122「PARP1抑制劑」的新藥臨床試驗申請(IND)已獲得中國國家藥品監督管理局 (NMPA)受理，擬用於治療晚期惡性腫瘤。 TQB3122是一款具有高選擇性和血腦屏障穿透能力的PARP1抑制劑，通過雙重機制發揮抗腫瘤作 用：一方面，競爭性抑制PARP1酶的催化活性，阻斷DNA單鏈斷裂修復；另一方面，通過 ...